Plasma IL-17A levels in NSCLC patients, at similar concentrations observed in the current study, have been reported to correlate with pneumonitis onset in patients with Stage IIIB-IV NSCLC undergoing immunotherapy [26]; however, a comparison to normal controls were not provided. The gene discussed is IL17A; the disease is pneumonitis.